SEC EDGARSEP 151 min read$CLOV

OLDAKOWSKI JOSEPH FRANK sold $103K of CLOV

OLDAKOWSKI JOSEPH FRANK (VP OF FINANCE AND CONTROLLER) sold 20,000 shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $5.16 ($0.10M total) on 2026-09-14.

Original reporting

SEC EDGAR · OLDAKOWSKI JOSEPH FRANK

Published Sep 15, 2026, 12:52 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 15, 2026, 1:08 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$CLOV

Bearish

medium confidence

Mentioned

$CLOV

Relevance

4/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$CLOVBearishLow

Why it matters

The insider sale is modest but noteworthy due to the officer's role; traders may watch for price reaction.

Market read

Primary disclosure of an insider sale; limited but actionable for short‑term traders.

What to watch

Potential upcoming earnings or strategic announcements that may offset the sale impact.

Relevance 4/10Novelty 4/10Timing: same-day filing on 2026-09-14

Background

Form 4 filing discloses insider transactions; investors monitor such sales for signals.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$CLOVBearishMedium confidence

Context

VP of Finance sold 20,000 shares for $103,200 on 2026-09-14, reducing his stake to 279,067 shares.

Expected impact

Potential short‑term pressure on CLOV price, likely 1‑2% dip.

Evidence & confidence

The sale size is modest relative to float, but insider status adds weight; market may react modestly.

Market effects

Sector

Minimal impact on health‑tech sector; similar insider sales have not moved sector trends.

Regional

U.S. market only; no regional ripple.

Global

Low; limited to CLOV shareholders.

Counterpoint

What could challenge this read

The sale could be routine portfolio rebalancing, not a negative signal.

Key entities

Company
Clover Health Investments, Inc.
U.S. listed health‑tech firm (ticker CLOV).
Insider
Joseph Frank Odlakowski
Vice President of Finance and Controller.

Read at source ← All news

SEP 15

$ASTHMed

Astrana Health, Clover Health, Alignment Healthcare, and Novavax Stocks Trade Down, What You Need To Know

Several healthcare stocks fell after bipartisan lawmakers introduced the Protecting Approved Care Act, which aims to reform Medicare Advantage plans. The bill could increase medical loss ratios and administrative burdens for insurers. Astrana Health (ASTH) fell 2.7%, Clover Health (CLOV) 4.8%, Alignment Healthcare (ALHC) 12.6%, and Novavax (NVAX) 3.6%.

financialcontent.com2 min

SEP 11

$CLOVHigh

Clover Health (CLOV) Gets New ‘Buy’ Call, Higher PT, Climbs 8.5%

Clover Health (CLOV) shares rose 8.53% to $4.71 after Deutsche Bank initiated coverage with a 'buy' rating and $6 price target, citing growth potential in Medicare Advantage and its technology platform. The company reported Q2 net income of $28M, up from a $10.6M loss YoY, with revenues increasing 55.6% to $743.2M. Medicare Advantage membership grew 48% to 157,309. Clover raised its net income and revenue guidance for the year. Hedge fund holdings in CLOV increased fourfold to $79.06M.

yahoo.com2 min

SEP 10

$CLOVMed

Clover Health (CLOV) Shares Skyrocket, What You Need To Know

Clover Health (CLOV) shares rose 8.5% after Deutsche Bank initiated coverage with a Buy rating and $6.00 price target, citing growth in Medicare Advantage, its Clover Assistant platform, and its risk model. The stock has seen high volatility, with a 24.2% drop last year due to disappointing earnings and lowered guidance. CLOV is up 96.9% YTD but trades 12.3% below its 52-week high.

financialcontent.com2 min

SEP 10

$PGNYHighAI 8/10

Spotting Winners: Progyny (NASDAQ:PGNY) And Health Insurance Providers Stocks In Q2

Progyny (PGNY) and other health insurers reported Q2 earnings, with revenues beating estimates by 2.8% but guidance below expectations. PGNY's revenue grew 5.3% YoY, missing EBITDA guidance. CVS Health (CVS) reported 7.3% YoY revenue growth, beating estimates. Molina Healthcare (MOH) saw a 4.8% YoY revenue decline. Alignment Healthcare (ALHC) grew 31.6% YoY, while Clover Health (CLOV) saw 55.6% YoY growth. Stocks have declined since earnings, except CLOV, which rose 4.3%.

tradingview.com3 min

SEP 3

$CLOVHighAI 8/10

Clover Health (CLOV) Turns Profitable As Medicare Membership Explodes

Clover Health (CLOV) reported Q2 2026 net income of $28M, reversing a $10.6M loss from the prior year. Medicare Advantage membership grew 48% YoY to 157,309. Revenue rose 55.6% to $743.2M, and adjusted EBITDA more than doubled. The company raised its full-year guidance, including adjusted EBITDA to $70M-$85M and GAAP net income to $20M-$35M. Cash and investments increased 13.8% YoY to $443.0M.

insidermonkey.com3 min

AUG 20